Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6552 DDI with Diltiazem in Healthy Participants
NCT06662396Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MK-6552 in narcolepsy, sponsored by Merck & Co. Primary endpoint: Maximum Plasma Concentration at 24 hours. Started Jun 2024; status: completed.
02
Drugs
MK-6552
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT06662396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06662396.